[Prognostic factors affecting survival of advanced gastric cancer patients on cancer chemotherapy].
Diverse factors which affect survival of advanced gastric cancer patients after the initiation of chemotherapy were investigated for 487 cases hospitalized in our department from 1963 to 1984 using Cutler & Ederer's Life Table Analysis Method. The patients from 1978 to 1984 survived longer than those from 1963 to 1972 and from 1973 to 1977. The survival was prolonged significantly in the cases with localized tumors, histology of well- or moderately-differentiated carcinomas and better performance status (PS), and in the cases receiving combined chemotherapy with BRM or in those responsive to cancer chemotherapy. The patients receiving the regimen with fluoropyrimidines, anthracyclines or BRM survived longer than those without these drugs. The survival rate, with the passage of years stated above, tended to improve even in cases with unfavorable prognostic factors such as un-resectable primary lesion, over 60 years of age, extensive tumors or PS3 and PS4. The similar change in survival rate was observed in the cases with chemotherapy + BRM treatment, in those receiving fluoropyrimidines, and MMC or other alkylating agents. The favorable prognostic factors detected in our studies were similar to the ones found in the past reports. Even in the cases with unfavorable prognostic factors the improvement in survival rate was made with the passage of years. We are encouraged by the results obtained, which suggest the progress of cancer chemotherapy.